A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Niki BioSolutions, Inc., through its subsidiaries, operates as a clinical-stage biopharmaceutical company and engages in the discovery, development, and commercialization of therapeutic products to treat oncology and infectious diseases. Its pipeline products include SACT-1, a repurposed drug candidate, which is in a Phase 1 clinical trial to treat neuroblastoma and other cancer types; ALS-4, a repurposed small molecule, which is in a Phase 1 clinical trial for the treatment of bacterial infections, such as staphylococcus aureus, mycobacterium tuberculosis, and pseudomonas aeruginosa. The company also develops SACT-COV19, a repurposed small molecule, which is in a preclinical trial for the treatment of coronavirus disease; SACT-2 and SACT-3; ALS-1, a small molecule, which is in a preclinical trial to treat bacterial infections caused by staphylococcus aureus, including methicillin-resistant staphylococcus aureus (MRSA); and ALS-2/3, a small molecule, which is in a preclinical trial for the treatment of gram+ve bacterial infections. The company was formerly known as Aptorum Group Limited and changed its name to Niki BioSolutions, Inc. in July 2026. Niki BioSolutions, Inc. was incorporated in 2010 and is headquartered in Princeton, New Jersey. Niki BioSolutions, Inc. operates as a subsidiary of Jurchen Investment Corporation.
Financial Summary
| Share Statistics | NIKI | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $8.0 | $252.6 | 6% |
|
| Shares Out (Mil) | 0.8 | 52.3 | 4% |
|
| Institutional Ownership | 2.9% | 92.1% | 4% |
|
| Float (Mil) | na | 40.2 | na |
|
| Beta | 0.17 | 0.95 | 11% |
|
| Avg Daily Volume (000s) | 423 | 455 | 56% |
|
| Price Change (52-week) |
(40.5%) | 52.9% | 19% |
|
| Growth | NIKI | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | (17.1%) | (9.9%) | 23% |
|
| EPS (5yr) | (15.9%) | 16.0% | 17 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | 21.6% | (15.6%) | 81% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | NIKI | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $38 | na |
|
| Net Income (TTM) (Mil) | ($1) | ($43) | 37% |
|
| EPS (TTM) | ($1.854) | ($1.600) | 16% |
|
| Operating Cash Flow (TTM) (Mil) | ($2) | ($31) | 29% |
|
| Net Cash Flow (TTM) (Mil) | na | $5 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $5 | 0% |
|
| Enterprise Value (Q1) (Mil) | ($2) | $180 | 3% |
|
| Valuation | NIKI | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.35 | 2.56 | 6% |
|
| P/E | na | 19.0 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | NIKI | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 63.8% | na |
|
| Net Margin | na | (67.3%) | na |
|
| ROA | (7.8%) | (49.8%) | 27% |
|
| ROE | (6.2%) | (55.5%) | 30% |
|
| Liabilities to Assets | 26.5% | 30.3% | 18% |
|
| F-Score | 2 | 3 | 7% |
|
Niki BioSolutions, Inc. did not pass any screens on 7/31/2026.
